



JRC TECHNICAL REPORT

A common data quality check procedure for European cancer registries

Carmen Martos, Francesco Giusti, Liesbet Van Eycken, Otto Visser

On behalf of the JRC Cancer Information Group and the ENCR
Steering Committee



European Network
of Cancer Registries

December 2023 update



This publication is a Technical report by the Joint Research Centre (JRC), the European Commission's science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The contents of this publication do not necessarily reflect the position or opinion of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. The designations employed and the presentation of material on the maps do not imply the expression of any opinion whatsoever on the part of the European Union concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Contact information

European Commission - Joint Research Centre
Directorate F – Health and Food
Cancer Information Group, Unit F.1 – Disease Prevention
Address: TP127, Via E. Fermi 2749, 21027 Ispra (Varese), Italy
Email: jrc-encr@ec.europa.eu

EU Science Hub

<https://joint-research-centre.ec.europa.eu>

JRC132486

Ispra: European Commission, 2023

© European Union, 2023



The reuse policy of the European Commission documents is implemented by the Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Unless otherwise noted, the reuse of this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence (<https://creativecommons.org/licenses/by/4.0/>). This means that reuse is allowed provided appropriate credit is given and any changes are indicated.

For any use or reproduction of photos or other material that is not owned by the European Union/European Atomic Energy Community, permission must be sought directly from the copyright holders.

- Cover page illustration, © Vitanovski / stock.adobe.com

How to cite this report: Martos, C., Giusti, F., Van Eycken, E., Visser, O., *A common data quality check procedure for European cancer registries*, European Commission, Ispra, Italy, 2023, JRC132486.

Contents

Abstract.....	2
Contributors.....	3
1 Introduction.....	4
2 Case definition and variables included in the quality checklist.....	5
2.1 Case definition.....	5
2.2 Variables and valid values.....	5
3 List of quality checks: internal consistency.....	12
3.1 Consistency within variables.....	12
3.2 Consistency between variables.....	13
3.2.1 Coherence between dates.....	13
3.2.2 Consistency between tumour data and demographic information.....	13
Consistency between age/ topography / morphology.....	13
Consistency between sex/ topography.....	16
3.2.3 Consistency between tumour variables.....	16
Consistency between basis of diagnosis/ morphology/ behaviour.....	16
Consistency between morphology/ grade.....	19
Consistency between topography/ laterality.....	22
Consistency between topography/ morphology.....	22
Consistency between morphology/ behaviour.....	30
3.2.4 Consistency between follow-up variables, basis of diagnosis and stage.....	31
Consistency between vital status, incidental finding of cancer at autopsy (autopsy), basis of diagnosis, duration of survival (survival) and stage.....	31
3.2.5 Consistency between stage/ treatment variables and other tumour variables.....	32
Other additional checks related to stage and treatment variables.....	33
4 Quality checklist for Multiple Primary Malignant Tumours.....	34
5 Conclusions.....	40
References.....	41
List of abbreviations and definitions.....	43
List of figures.....	44
List of tables.....	45

Abstract

The aims of population-based cancer registries (CRs) are: a) to obtain information from all new cases in a well-defined geographic area in order to assess the magnitude of the cancer burden and its evolution, and b) to provide a basis for research on cancer causes and outcome (incidence, prevalence and survival).

The reliability and utility of the information provided by CRs depends on the quality of the data collected. The JRC Technical report "A common data quality check procedure for European cancer registries" is a reference document to harmonize the cancer quality checks among the European population-based cancer registries.

The report includes recommendations for checking internal consistency of the cancer incidence data. It will be used for updating the Quality Check Software developed by the Joint Research Centre (JRC) in collaboration with the European Network of Cancer Registries (ENCR).

Checks for validating internal consistency within and between variables are detailed. Allowed values for each variable are based on the current data call protocol that the European cancer registries are following to update the European Cancer Information System (ECIS).

Concerning consistency between variables several checks are proposed to validate: 1) coherence of dates; 2) consistency between tumour data and demographic information; 3) consistency between tumour variables; 4) consistency between follow-up variables, basis of diagnosis and stage and; 5) consistency between stage, treatment variables and other tumour variables. In addition to the intra-record checks, inter-record checks are proposed for validating multiple primary tumours.

Contributors

JRC Cancer Information Group

Randi, G., Neamtiu, L., Manuela F., Dimitrova, N., Dyba, T., Carvalho, R. Bettio, M.

Members of the current and previous Steering Committee of the ENCR contributing to the project

Arndt, V., Cuccaro, F., Gavin, A., Lambe, M., Trojanowski, M., Monnereau, A., Sanchez, M.J., Stracci, F., Eden, M., Šekerija, M., Bray, F., Miranda, A., Storm, H.

1 [▫] Introduction

The aims of population-based cancer registries (CRs) are: a) to obtain information from all new cases in a well-defined geographic area in order to assess the magnitude of the cancer burden and its evolution, and b) to provide a basis for research on cancer causes and outcome (incidence, prevalence and survival).

In the last decades, registries have had a substantial role in the planning and evaluation of cancer control activities, and the care of individual cancer patients. Therefore, CRs contribute to monitoring the impact and effectiveness of policy implementation (1-3). The reliability and utility of the information provided by CRs depends on the quality of the data collected.

Several aspects are usually regarded when evaluating the quality of the data in CRs: comparability, completeness and validity. An additional quality indicator - the timeliness of registry procedures is also considered (4, 5).

A variety of methods and tools has been used to check the data validity of CRs (6-9). Therefore, the European Network of Cancer Registries (ENCR), in cooperation with the Joint Research Centre (JRC), were working to establish a comprehensive and standardised list of data quality checks to be adopted by European CRs and European projects that addressed the fragmented and sometimes conflicting situation regarding validation of data collected for different purposes.

The adoption of a common list of variables, formats and standard data quality checks is needed to improve the harmonisation of European cancer data giving CRs the opportunity to participate easily in different international projects.

In 2014 the JRC Technical report "A proposal on cancer data quality checks: one common procedure for European cancer registries" was published as the outcome of the Working Group on Cancer Data Quality Check (10). The document was the result of a collaborative project between the JRC, the ENCR and the Working Group.

An updated version (1.1) of the JRC Technical report was published in 2018 (11).

With respect to the first version (1.0), in the updated version (1.1) of the report, the quality checklist of warnings for multiple primary malignant tumours (MPMT) according to the current International Rules for Primary Cancers published in 2004 was added. Moreover, the "Valid combinations for behaviour and topography/morphology" in the previous version of the report (1.0) were discarded.

The current JRC Technical report "A common data quality check procedure for European cancer registries" includes a review of the data quality checklist, based on the experience gained from the validation of the data submitted by the European CRs in the 2015 ENCR-JRC Data Call.

The International Classification of Diseases for Oncology, Third edition, Second Revision Morphology (ICD-O-3.2) (12) and the TNM Eight Edition (13) were considered. The quality checklist for MPMT has been updated according to the updated table "Groups of malignant neoplasms considered to be histologically different for the purpose of defining multiple tumours" to be used with ICD-O-3.2 (14) and some checks related to stage and treatment have been reviewed.

The proposed quality checklist allows the identification of impossible codes or code combinations, unlikely codes or code combinations and possible but very rare code or code combinations.

2 Case definition and variables included in the quality checklist

The cancer data quality check list included in this report is based on the Call for Data Protocol for European Population - Based Cancer Registries (15).

2.1 Case definition

- All primary malignant tumours (behaviour=3), including basal cell and squamous cell carcinomas of skin.
- In situ tumours (behaviour=2): breast (ICD-O C50), urothelial tumours (C65-C68), ovary (C56) and skin melanoma.
- Uncertain behaviour tumours (behaviour=1): thymoma (8580/1-8585/1), urothelial tumours (C65-C68), ovary (C56) and central nervous system (CNS) (C70-C72, C75.1-C75.3).
- Benign tumours (behaviour=0) of the CNS (C70-C72 and C75.1-C75.3).

Gastrointestinal stromal tumours (GIST) and gastroenteropancreatic neuroendocrine tumours are considered with behaviour=3 as they are in the ICD-O-3.2.

2.2 Variables and valid values

Table 1 shows the list of the variables considered: description, missing/ unknown values and the allowed values on which quality checks are based.

Some variables included in this report are not listed in the current Call for Data Protocol (15). Nevertheless, they are considered in the report to provide a standard coding and checking system to improve the data harmonisation in the European cancer registries. For example, laterality is not included in the protocol but it is important for recording multiple primary tumours according to the current international rules for multiple primary cancers (16).

Table 1. Variable description, missing/unknown and allowed values.

Variable description	Missing/unknown values	Coding and allowed values
Patient variables		
Patient identification number	Not allowed	According to registry coding system ¹
Day of birth	99	Range of allowed values: from 1 to 31, 99
Month of birth	99	Range of allowed values: from 1 to 12, 99 Warning for value = 99
Year of birth	9999	Range of allowed values: >1842 and ≤the current year, 9999 Warning for value = 9999
Sex	9	Allowed values: 1, 2, 3, 9 1→Male 2→Female 3→Other Warning for value=9

Table 1. Continued

Variable description	Missing/unknown values	Coding and allowed values
Tumour variables		
Tumour identification code	According to registry coding system ¹	According to registry coding system ¹ Not allowed to have duplicate combination of the two variables: Patient identification code + tumour identification code in the same dataset
Geographical area of residence at diagnosis	Postal code, zip code, municipalities, etc. (according to registry coding system) ¹	According to registry coding system ¹ It is recommended to check the code values with a list of all possible allowed values to identify errors in coding this variable. The coding system used for the CR should allow to code residence area according to NUT Classification used by EUROSTAT (17)
Age at diagnosis in years	999	Range of allowed values: ≥ 0 and < 121 , 999 Warning for value=999 if complete date of birth and/or date of incidence are missing or unknown
Day: date of incidence ²	99	Range of allowed values: from 1 to 31, 99
Month: date of incidence ²	99	Range of allowed values: from 1 to 12, 99 Warning for value=99
Year: date of incidence ²	Not allowed	Range of allowed values: > 1941 and \leq the current year
Basis of diagnosis ³	9	Allowed values: 0, 1, 2, 4, 5, 7, 8, 9 0 → Death certificate only (DCO) 1 → Clinical 2 → Clinical investigation 4 → Specific tumour markers 5 → Cytology 7 → Histology 8 → Cytogenetic and/or molecular testing Warning for value=9
ICD-O-3 topography (topography of the metastasis is not admitted)	Not allowed	Valid code in ICD-O-3 The code for unknown primary site is C80.9

Table 1. *Continued*

Variable description	Missing/unknown values	Coding and allowed values
ICD-O-3 morphology	Not allowed	Valid code in any ICD-O-3 version The code for unknown morphology is 8000 for solid tumours, 9590 for lymphoma NOS and 9800 for Leukaemia NOS
ICD-O-3 behaviour	Not allowed	Allowed values: from 0 to 3 Behaviour 6 (malignant, metastatic) and behavior 9 (Malignant, uncertain whether primary or metastatic) should be coded in the cancer registry as behavior 3
ICD-O-3 grade ⁴	9	Allowed values: 0-9 1 → Well differentiated 2 → Moderately differentiated 3 → Poorly differentiated 4 → Undifferentiated, anaplastic 5 → T-cell; T-precursor 6 → B-Cell; Pre-B; B-precursor 7 → Null cell; Non T-non B 8 → NK cell (natural killer cell) Non-applicable = 0
Laterality of paired organs	9	Allowed values: 0, 1, 2, 3, 4, 9 1 → Right 2 → Left 3 → Unilateral, NOS 4 → Bilateral Non-applicable = 0
Variables related to the follow-up		
Vital status at last contact	9	Allowed values: 1, 2, 9 1 → Alive 2 → Dead Warning for value=9
Day of the last known vital status	99	Range of allowed values: from 1 to 31, 99
Month of the last known vital status	99	Range of allowed values: from 1 to 12, 99 Warning for value=99
Year of the last known vital status	9999	Range of allowed values: >1941 and ≤ the current year Warning for value=9999

Table 1. *Continued*

Variable description	Missing/unknown values	Coding and allowed values
Duration of survival in days	99999	≥0 Warning for value=99999 if complete date of incidence and/or date of last known vital status are missing or unknown
International Classification of Diseases (ICD) edition used for coding cause of death	99	Range of allowed values: > 0 and ≤ 12 Blank → not applicable
Official underlying cause of death	99999	Valid code in ICD according to ICD edition Blank → not applicable
Stage variables		
TNM edition	99	Allowed values: > 0 and ≤ 10, 99 It has to be periodically updated
TNM: clinical T-category (cT)	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
TNM: clinical N-category (cN)	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
TNM: clinical M-category (cM)	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
TNM: pathological T-category (pT)	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
TNM, pathological N-category (pN)	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
TNM, pathological M-category (pM)	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
TNM stage	9	Valid values according to TNM Classification and edition (references 13, 22-25) Blank → not applicable
Toronto Childhood Cancer Stage Tier 1 for paediatric tumour	9	Valid values according to Toronto guidelines (references 26, 27) Blank → not applicable
Toronto Childhood Cancer Stage Tier 2 for paediatric tumours	9	Valid values according to Toronto guidelines (references 26, 27) Blank → not applicable
Essential TNM stage	9	Valid values according to the Essential TNM guidelines (reference 28)

Table 1. Continued

Variable description	Missing/unknown values	Coding and allowed values
Ann Arbor staging system	9	Coding lymphomas Allowed values: I, II, III, IV, 9 Modifiers: A, B, S, E, X ^a Blank → not applicable
Lugano staging system	9	Coding lymphomas Allowed values: I, II, III, IV, 9 Modifiers: A, B, S, E, bulky ^b Blank → not applicable
Dukes' stage ⁵	9	Coding colorectal carcinoma Allowed values: A, B, C, D, 9 Blank → not applicable
Summary extent of disease (EoD)	9	Allowed values: 1,2,3,4,5,9 1 → Confined 2 → Adjacent tissues, and/or regional lymph-nodes 3 → Distant organs 4 → Not confined but not specified whether code 2 or 3 applies 5 → Not distant metastasis but not specified whether code 1 or 2 applies 9 → Unknown Blank → not applicable
FIGO stage	9	For coding gynaecological tumours Allowed values: <ul style="list-style-type: none"> • Ovary and fallopian tube carcinoma (2014 revision): I, Ia, Ib, Ic, Ic1, Ic2, Ic3, II, IIa, IIb, III, IIIa, IIIa1, IIIa1(i), IIIa1(ii), IIIa2, IIIb, IIIc, IV, IVa, IVb, 9 • Endometrium carcinoma (2009 revision): 0, I, Ia, Ib, II, III, IIIa, IIIb, IIIc, IIIc1, IIIc2, IV, IVa, IVb, 9 • Cervix carcinoma (2018 revision): I, IA, IA1, IA2, IB, IB1, IB2, IB3, II, IIA, IIA1, IIA2, IIB, III, IIIA, IIIB, IIIC, IIIC1, IIIC2, IV, IVA, IVB, 9 • Vagina: 0, I, II, III, IV, IVa, IVb, 9 • Vulva (2021 revision): I, IA, IB, II, III, IIIA, IIIB, IIIC, IV, IVA, IVA(i), IVA(ii), IVB, 9 • Uterine choriocarcinoma: I, II, III, IV, 9 Blank → not applicable
First course of Treatment variables (coding and allowed values are based on the current Call for Data Protocol (reference 15). These checks will be updated according to the ENCR recommendations on treatment data harmonisation when they are published)		
Surgery ^{6,7} (Resection of the primary tumour)	9	Allowed values: 0, 1, 2, 3, 9 0 → No 1 → Yes, without specification 2 → Yes, local surgery only ⁸ 3 → Yes, 'operative' surgery ⁹

Table 1. Continued

Variable description	Missing/unknown values	Coding and allowed values
Radiotherapy	9	Allowed values: 0, 1, 2, 3, 9 0 -> No 1 -> Yes, without specification 2 -> Yes, neoadjuvant (pre-operative) radiotherapy 3 -> Yes, adjuvant (post-operative) radiotherapy
Chemotherapy	9	Allowed values: 0, 1, 2, 3, 4, 9 0 -> No 1 -> Yes, without other specification 2 -> Yes, neoadjuvant (pre-operative) 3 -> Yes, adjuvant (post-operative) 4 -> Yes, both neoadjuvant and adjuvant
Targeted therapy ⁽¹⁰⁾ (including monoclonal antibodies)	9	Allowed values: 0, 1, 9 0 -> No 1 -> Yes
Immunotherapy (excl. monoclonal antibodies)	9	Allowed values: 0, 1, 9 0 -> No 1 -> Yes
Hormone therapy	9	Allowed values: 0, 1, 9 0 -> No 1 -> Yes
Other or unspecified systemic therapy	9	Allowed values: 0, 1, 2, 3, 9 0 -> No 1 -> Yes, without other specification 2 -> Yes, neoadjuvant (pre-operative) 3 -> Yes, adjuvant (post-operative)
Stem cell transplantation	9	Allowed values: 0, 1, 9 0 -> No 1 -> Yes

(1) Depending on the registry coding

(2) According to [ENCR recommendation for incidence date](#) (18)

(3) According to [ENCR recommendation for basis of diagnosis](#) (19)

(4) Except for central nervous system tumours (these tumours should be coded according to the WHO grading system Table 27 of the ICD-O-3.1 (20) and urothelial tumours (these tumours should be coded according to the [ENCR Recommendations for Recording and Reporting of Urothelial Tumours of the Urinary Tract](#) (21)

(5) Obsolete classification, mentioned because of historical series

(6) If available, type of surgery (local surgery [2] versus operative surgery [3]) should be coded for solid cancers of the following cancer sites: C01-C06, C16-C20, C30-C34, C53-C55, C61 and C65-C68. For other cancers, code 1 (surgery without specification) suffices.

(7) If both local surgery and operative surgery were performed for the same tumour, operative surgery should be coded.

(8) The following procedures should be coded as local surgery: polypectomy (mainly gastro-intestinal tract), transurethral resection (TUR; bladder & other urinary tract), cone biopsy/loop excision (cervix), as well as all other procedures which leave the organ in situ, such as cryosurgery, laser coagulation, thermoablation, radiofrequency ablation (RFA), etc.

(9) This includes all resections of the tumour which require the removal of an organ or a major part of that organ, such as a lobectomy, hemicolectomy, hysterectomy, cystectomy, prostatectomy, etc.

(10) Targeted therapy comprises all drugs that block the growth of cancer cells by inhibition of certain pathways in the cancer cell.

Traditional chemotherapy also affects other cells in the body that divide quickly. The main categories of targeted therapy are small molecules (mostly tyrosine kinase inhibitors such as imatinib and many other -nibs) and monoclonal antibodies (such as rituximab and many other -mabs). Monoclonal antibodies are considered a form of immunotherapy but should be coded as targeted therapy.

- (^a) A: asymptomatic;
B: presence of B symptoms (including fever, night sweats and weight loss of $\geq 10\%$ of body weight over 6 months);
E: involvement of a single, extranodal site, contiguous or proximal to a known nodal site (stages I to III only; additional extranodal involvement is stage IV);
S: splenic involvement;
X: bulky nodal disease: nodal mass $>1/3$ of intrathoracic diameter or 10 cm in dimension.
- (^b) A: asymptomatic;
B: presence of systemic symptoms (fever/night sweats/unexplained weight loss);
E: refers to extranodal contiguous extension that can still be encompassed within a irradiation field appropriate for nodal disease of the same anatomic extent;
Bulky: if a single nodal mass >10 cm or $>1/3$ of transthoracic diameter.

3 List of quality checks: internal consistency


3.1 Consistency within variables

Most of the quality checks for single variables concern allowed values are detailed in **Table 1**. Nevertheless, other specific quality checks detailed below are required for dates.

Regarding 'dates', some simple rules are necessary when they are collected as three independent variables reporting 'day', 'month' and 'year' (**Figure 1**):

- if the variable 'month' is equal to January (1), March (3), May (5), July (7), August (8), October (10) or December (12) the range of values for the variable day is from 1 to 31;
- if the variable 'month' is April (4), June (6), September (9) or November (11) the range of values for the variable 'day' is from 1 to 30

Figure 1. Range of values for the variable 'day' according to variables 'month' and 'year'.



- if the variable 'month' is February (2) the range of values for the variable 'day' is from 1 to 28, except for leap-years in which the range of values for the 'day' is from 1 to 29. The algorithm to define a leap-year is the following:
 - it is a year divisible by 4 (*i.e.* 2004, 2008, etc.). This rule does not apply to centennial years (those exactly divisible by 100 (*i.e.* 1900, 2100, etc.);
 - it is a centennial year (exactly divisible by 100) and it is also exactly divisible by 400 (like 2000, 2400).

Age at diagnosis: measured as the age in years at the patient's last birthday. Age could be calculated if both incidence and birth dates are registered (or at least the incidence year and birth year). It is recommended using algorithms to impute the dates before calculating the age, when possible. The range of values must be between 0 and 120.

This variable could be computed if at least both incidence and birth years are available:

- If only year of diagnosis and birth are available, then age at diagnosis is computed as a difference:

$$\text{Age at diagnosis} = \text{year of incidence} - \text{year of birth}$$

- If the month and year of both dates are known, then age at diagnosis is computed as:

$$\text{Age at diagnosis} = \frac{[(\text{year of incidence} * 12 + \text{month of incidence}) - (\text{year of birth} * 12 + \text{month of birth})]}{12}$$

→ Integer

- If the month of diagnosis and birth are known and equal, and the day of diagnosis is earlier than the day of birth, then 1 is subtracted from the calculated age.

Once computed, the age at diagnosis should be compared with what was provided by the CRs, and be consistent according to the following rule:

$$\text{Age at diagnosis computed} = \text{registered age at diagnosis} \pm 1$$

TNM and stage grouping values depend on the cancer topography, morphology and edition of the TNM classification. The clinical (cT, cN, cM) and pathological (pT, pN, pM) categories and stage should be coded according to the corresponding version of the TNM classification (13, 22-25).

3.2 Consistency between variables

3.2.1 Coherence between dates

The proposed rules below check for coherence between variables: *date of birth*, *date of incidence* and *date of the last known vital status*:

- Date of birth ≤ Date of incidence.

This rule is valid unless the case was diagnosed in utero if the diagnosis is in utero, the difference in months between dates should be no more than nine.

- Date of birth ≤ Date of the last known vital status.
- Date of incidence ≤ Date of the last known vital status.

For each comparison between dates, if years are known but at least one of the months is unknown/missing, then the years are only compared. Similarly, if the day(s) is (are) unknown/missing, only the years and months are compared.

3.2.2 Consistency between tumour data and demographic information

- **Consistency between age/ topography / morphology**

Some cancers occur almost exclusively in certain age groups such as retinoblastoma (tumour of young children) or prostate cancer in older men; therefore, some combinations age/topography/morphology are unlikely and should result in a warning.

Nevertheless there are other age and tumour type combinations that are not unlikely *but* rare. A warning for these combinations improves the precision of these rare tumours.

Table 2 shows unlikely and rare combinations by age group and tumour type. The updated morphologies included in the ICD-O-3.2 (12) and frequencies of warnings found in the data submitted through the 2015 ENCR-JRC data call by the European CRs have been taking into account for updating this table.

Table 2. Unlikely and rare combinations of age and tumour type.

Age group [years]	Morphology	Topography
0-2	Hodgkin lymphoma: 9650-9667	–
> 9	Retinoblastoma: 9510-9514	–
> 8	rhabdoid tumour: 8963	C64.9
0-8	Renal carcinoma: 8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8143, 8155, 8190-8201, 8210, 8211, 8221-8231, 8240, 8241, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8573	C64.9
	8312	–
> 19	Hepatoblastoma: 8970	–
0-8	Hepatic carcinoma: 8010-8041, 8050-8075, 8082, 8120-8122, 8140, 8141, 8143, 8155, 8190-8201, 8210, 8211, 8230, 8231, 8240, 8241, 8244-8246, 8260-8263, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8573	C22.0, C22.1
< 20	Cholangiocarcinoma: 8160/3	
	Combined hepatocellular carcinoma and cholangiocarcinoma: 8180/3	
0-5	Osteosarcomas: 9192-9195	–
0-5	Chondrosarcoma: 9220-9230	
> 7	Malignant extra-cranial and extra-gonadal germ cell: 9060-9065, 9070-9072, 9080-9085, 9100-9105	C00-C37, C40-C47, C50, C60-C61, C63-C69, C73-C75.0, C75.4-C76.8, C80
0-14	Gonadal carcinoma: 8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8143, 8190-8201, 8210, 8211, 8221-8241, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8380-8384, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8573, 9014, 9015	C56, C62
	Gonadal carcinoma: 8313, 8441, 8450, 8460-8471, 9000	–

Table 2. *Continued*

Age group [years]	Morphology	Topography
0-5	Thyroid carcinoma: 8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8155, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8510, 8560-8573	C73
	Thyroid carcinoma: 8330-8347, 8350	-
0-5	Nasopharyngeal carcinoma: 8010-8041, 8050-8075, 8082, 8083, 8120-8122, 8130-8141, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8500-8576	C11
0-4	Skin carcinoma: 8010-8041, 8050-8075, 8078, 8082, 8090-8110, 8140, 8143, 8147, 8190, 8200, 8240, 8246, 8247, 8260, 8310, 8320, 8323, 8390-8420, 8430, 8480, 8542, 8560, 8570-8573, 8940, 8941	C44
0-4	Carcinoma, NOS: 8010-8084, 8120-8157, 8190-8264, 8290, 8310, 8314-8315, 8320-8325, 8380-8384, 8430-8440, 8452-8454, 8480-8586, 8588-8589, 8940-8941, 9010-9016, 9020, 9030	C00-C10, C12-C21, C23-C39, C48, C50-C55, C57-C61, C63, C65-C72, C75-C76, C80
0-14	Mesothelial neoplasms: 9050-9053	Any
0-14	8085-8110, 8158, 8161-8175, 8265-8281, 8300, 8311, 8316-8319, 8348-8349, 8360-8375, 8390-8420, 8442-8443, 8451, 8472-8474, 8587	C15, C19, C20, 21, C23, C24, C38.4, C50-C55
5-14	8010-8084, 8120-8157, 8190-8264, 8290, 8310, 8314-8315, 8320-8325, 8330-8347, 8350, 8380-8384, 8430-8440, 8452-8454, 8480-8486, 8588	
< 25	Multiple myeloma: 9732 Chronic lymphocytic leukaemia: 9823 Chronic myeloid leukaemia: 9876, 9945	Any
0-19	8085-8110, 8158, 8161-8175, 8265-8281, 8300, 8311, 8316-8319, 8348-8349, 8360-8375, 8390-8420, 8442-8443, 8451, 8472-8474, 8587	C60
5-19	8010-8084, 8120-8157, 8190-8264, 8290, 8310, 8314-8315, 8320-8325, 8330-8347, 8350, 8380-8384, 8430-8440, 8452-8454, 8480-8486, 8588	
15-19	8313, 8441, 8450, 8460-8471, 9000	
< 35	Adenocarcinoma: 8140	C61

Age group [years]	Morphology	Topography
> 55	Choriocarcinoma: 9100	C58
>14	8910, 8960, 8981, 8991, 9470, 9687/9826	Any
>14	Juvenile myelomonocytic leukaemia: 9946	Any

Consistency between sex/ topography

Some sex/topography combinations are impossible. Invalid combinations are presented in **Table 3**.

Table 3. Invalid sex and topography combinations.

Sex=1 (male)	Sex=2 (female)
C51 Vulva	C60 Penis
C52 Vagina	C61 Prostate gland
C53 Cervix uteri	C62 Testis
C54 Corpus uteri	C63 Other and unspecified male genital organs
C55 Uterus, NOS	
C56 Ovary	
C57 Other and unspecified female genital organs	
C58 Placenta	

3.2.3 Consistency between tumour variables

- Consistency between basis of diagnosis/ morphology/ behaviour

It is unlikely for specific morphologies not to have undergone a histological/ cytological examination. Nevertheless, some combinations are considered as exceptions. ENCR recommendations have been followed for 'specific' morphology codes in absence of microscopic verification (19).

Morphology codes for cases with 'death certificate only' (DCO) are allowed when they can be identified from the underlying cause of death code (International Classification of Diseases 10th Revision). **Table 4** shows the accepted combinations between basis of diagnosis (BoD) and morphology. Combinations not included in **Table 4** need to be verified.

Table 4. Valid combinations for basis of diagnosis, morphology and behaviour by topography.

Basis of diagnosis	Morphology and behaviour code allowed	Comments
0 (Death Certificate Only)	8000/3 8170/3 (C22.0 ICD-10) 81603 (C22.1 ICD-10) 8970/3 (C22.2 ICD-10) 9120/3 (C22.3 ICD-10) 8800/3 (C22.4 ICD-10) 8010/3 (C22.7 ICD-10) 8720/3 (C43 ICD-10) 9050/3 (C45 ICD-10) 9140/3 (C46 ICD-10) 9590/3-9993/3 (C81-C96/D45-D47 ICD-10)	Any morphology code could be included in cases with DCO if the morphology text is included in the death certificate. Nevertheless, for checking purposes only morphology codes included in the ICD-O-10 codes are accepted.
1 (Clinical)	8000/3 (*), 8720/3 (C44, C69.0, C69.3, C69.4), 9120/3 (C44.5 ^a), 9510/3 (C69.2), 9140/3 (C44)	(*) Any topography ^a Angiosarcoma of the skin of the breast following radiotherapy of the breast
2 (Clinical investigation)	8000/3 (*), 8000/0 (C70-C72, C75.1-C75.3), 8000/1 (C70-C72, C75.1-C75.3), 8720/3 (C69.0, C69.3, C69.4), 8960/3 (C64), 8970/3 (C22), 9510/3 (C69.2), 8170/3 (C22.0), 8150/3 (C25.4), 8160/3 (C22.1, C24.0, C24.9), 8240/3 (C17), 8453/2 (C25), 8453/3 (C25), 8800/3 (*), 8850/3(*), 8890/3(*), 9120/3 (*), 9180/3 (C40, C41), 9220/3 (C40, C41), 9370/3 (C41.0), 9080/0 (C71, C75.1, C75.3), 9080/1 (C71, C75.1, C75.3), 9080/3 (C71, C75.1, C75.3), 9161/1 (C71, C72.0), 9350/1 (C75.2), 9360/1 (C75.3), 9361/1 (C75.3), 9362/3 (C75.3), 9380/39 (C71, C72.0), 9380/32 (C71, C72.0), 9380/33 (C71, C72.0), 9383/1 (C71.5, C71.7), 9384/1 (C71.5, C71.7), 9390/0 (C71.5, C71.7), 9390/1 (C71.5, C71.7), 9390/3 (C71.5, C71.7), 9391/3 (C71.5, C71.7, C72.0), 9392/3 (C71.5, C71.7, C72.0), 9394/1 (C72.0, C72.1), 9395/3 (C75.3), 9400/39 (C71, C72.0), 9400/32 (C71, C72.0), 9401/33 (C71, C72.0), 9412/1 (C71), 9413/0 (C71), 9421/1 (C71, C72.0, C72.3), 9440/3 (C71, C72.0), 9450/39 (C71), 9450/32 (C71), 9451/33 (C71), 9470/3 (C71.6), 9473/3 (C71, C72.0), 9492/0 (C71, C72.0, C75.1), 9493/0 (C71.6), 9505/1 (C71, C72.0), 9506/1 (C71), 9509/0 (C71), 9509/1 (C71, C72.0), 9530/0 (C70), 9539/1 (C70), 9530/3 (C70), 9560/0 (C72.4, C72.5), 9590/3 (C71), 9751/3 (C34, C41, C71**)	(*) Any topography (**) Other topographies are possible

Table 4. *Continued*

Basis of diagnosis	Morphology and behaviour code allowed	Comments
4 (Specific tumour markers)	8000/3 (C18-C20)	Carcinoembryonic antigen (CEA)
	8170/3 (C22.0)	Alfa-fetoprotein (AFP)
	8000/3 (C23- C25)	Cancer antigen 19-9 (CA 19-9)
	8000/3 (C56)	Cancer antigen 125 (CA-125)
	8000/3 (C61)	Prostate-specific antigen (PSA)
	9100/3 (C58)	Human chorionic gonadotropin (HCG)
	9064/3 (C56, C62)	HCG
	9065/3 (C62)	AFP (+/- HCG)
	8240/3	Chromogranin A
	8151/3 (C25)	Insulin
	8152/3 (C25)	Glucagon
	8153/3 (C16, C17.0, C25)	Gastrin
	8155/3 (C25)	Vasoactive intestinal peptide (VIP)
	8156/3 (C17.0, C25)	Somatostatin
	8241/3	Serotonin
	8158/3	Adrenocorticotrophic hormone (ACTH) and other hormones
	8345/3 (C73)	Calcitonin
	9500/3	Catecholamine degradation products (homovanilic acid [HVA], vanillylmandelic acid [VMA])
	8271/3 (C75.1)	Prolactin
	8272/3 (C75.1)	Growth hormone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), ACTH, thyroid stimulating hormone (TSH)
	8700/3 (C74.1)	Catecholamines, chromogranin A
	9732/3 (C42.1)	M-protein (IgG, IgM, IgA) >30g/L
	9761/3 (C42.0)	IgM

Basis of diagnosis	Morphology and behaviour code allowed	Comments
5 (Cytology)	All morphologies except any in situ carcinoma and 8023/3, 9385/3, 9396/3, 9445/3, 9475/3-9478/3, 9806/3, 9807/3, 9812/3-9819/3, 9865/3, 9866/3, 9869/3, 9875/3-9879/3, 9896/3, 9897/3, 9911/3, 9912/3, 9965/3-9968/3, 9986/3	
7 (Histology)	All morphologies except 8001/3, 8023/3, 9385/3, 9396/3, 9445/3, 9475/3-9478/3, 9806/3, 9807/3, 9812/3-9819/3, 9865/3, 9866/3, 9869/3, 9876/3-9879/3, 9896/3, 9897/3, 9911/3, 9912/3, 9965/3-9968/3, 9986/3	
8 (Cytogenetic and/or molecular testing)	8023, 9385, 9396, 9400, 9401, 9445, 9450, 9451, 9475, 9476, 9477, 9478, 9806, 9807, 9812-9819, 9865, 9866, 9869, 9875, 9876, 9877, 9878, 9879, 9896, 9897, 9911, 9912, 9965-9968, 9986	
9 (Unknown)	All morphologies	

- Consistency between morphology/ grade

Only malignant tumours (behaviour=3) should be graded, except CNS, urothelial tumours and ductal carcinoma in situ of breast.

CNS tumour grade should be coded according to the WHO grading system (table 27 of the ICD-O-3.1 in pages 28 and 29) (20).

Urothelial tumour grade should be coded according to the ENCR Recommendations for Recording and Reporting of Urothelial Tumours of the Urinary Tract (21).

The combination between a 'behaviour' code less than 3 and a 'grade' code less than 9 and different from 0 or blank will be considered as an error, except for CNS, urothelial tumours and ductal carcinoma in situ of breast.

Grade and morphology values for urothelial tumours and ductal carcinoma in situ of breast with behaviour less than 3 are included in **Table 5**.

Table 5. Valid morphology and grade combinations for urothelial tumours and ductal carcinoma in situ of breast with behaviour less than 3.

Morphology/behaviour	Grade values
Urothelial tumours: 8120/2 8130/2	1, 3 1, 3
Ductal carcinoma in situ of breast : 8500/2	
Low grade or grade I	1
Moderate grade or grade II	2
High grade or grade III	3

Grade values and the allowed corresponding morphology codes for haematological malignancies are shown in **Table 6**.

Table 6. Valid morphology and grade combinations for haematological malignancies.

Grade→	5	6	8
Morphology	9700-9702, 9705, 9708, 9709, 9714-9719, 9724-9726, 9729, 9800, 9801, 9805-9807, 9809, 9820,9827, 9831, 9834, 9837	9591, 9596, 9597, 9670,9671, 9673, 9678-9680,9684, 9687-9691, 9695, 9698, 9699, 9712, 9728, 9731, 9732, 9734, 9737, 9738, 9761, 9762, 9800, 9801, 9805-9808, 9811, 9812-9818, 9820, 9823, 9826, 9833, 9836, 9940	9719, 9727, 9831, 9948

The combination between **grades 5-8** and **morphology out of the range 9590-9993** is **impossible**.

Grade values from 1 to 4 are not allowed for morphology range 9590-9993 **except for** 9801/34.

Some terms in ICD-O-3 carry an implied statement of grade; therefore an appropriate grade code could be associated. These combinations are specified in the following **Table 7**.

Table 7. Morphology code and description, and correct associated grade for ICD-O-3 terms with implied statement of grade.

Morphology code	Morphology description	Grade
8020/3	Carcinoma, undifferentiated, NOS	3, 4
8021/3	Carcinoma, anaplastic, NOS	4
8240/3	Neuroendocrine carcinoma, well-differentiated Neuroendocrine tumour, grade 1 Neuroendocrine carcinoma, low grade	1
8246/3	Poorly differentiated neuroendocrine neoplasm	3
8249/3	Neuroendocrine carcinoma, moderately differentiated Neuroendocrine tumour, grade 2 Neuroendocrine tumour, grade 3	2, 3
8331/3	Follicular adenocarcinoma, well-differentiated	1
8332/3	Follicular adenocarcinoma, moderately differentiated Follicular carcinoma, moderately differentiated	2
8337/3	Poorly differentiated thyroid carcinoma	3
8585/3	Well-differentiated thymic carcinoma	1
8631/3	Sertoli-Leydig cell tumour, poorly differentiated	3
8634/3	Sertoli-Leydig cell tumour, poorly differentiated, with heterologous elements	3
8830/3	Undifferentiated high grade pleomorphic sarcoma of bone	4
8851/3	Liposarcoma, well-differentiated, NOS	1
9062/3	Seminoma, anaplastic	4
9082/3	Malignant teratoma, undifferentiated Malignant teratoma, anaplastic	4
9187/3	Low grade central osteosarcoma	1
9362/3	Pineal parenchymal tumour of intermediate differentiation	2, 3
9382/3	Anaplastic oligoastrocytoma	3
9390/3	Choroid plexus papilloma, anaplastic	3
9401/3	Astrocytoma, anaplastic	3
9440/3	Glioblastoma	4
9451/3	Oligodendroglioma, anaplastic	3
9511/3	Retinoblastoma, differentiated	1
9512/3	Retinoblastoma, undifferentiated	4

- Consistency between topography/ laterality

Laterality' that means 'bilateral and separated topographies' should be coded for those paired organs for which such information may be relevant for clinical or epidemiological reasons (recording multiple primary cancers).

Therefore, laterality has a valid code from 1 to 4 (**Table 1**) for the following topographies:

List of paired organs for which it is suggested to collect laterality:

- C07 Parotid gland
- C09 Tonsil
- C30 Nasal cavity/middle ear
- C34 Lung
- C384 Pleura
- C400 Long bones of upper limb and scapula
- C401 Short bones of upper limb
- C402 Long bones of lower limb
- C403 Short bones of lower limb
- C413 Rib and clavicle
- C414 Pelvic bones (excluding sacrum, coccyx, and symphysis pubis)
- C441 Skin of eyelid
- C442 Skin of external ear
- C446 Skin of arm and shoulder
- C447 Skin of leg and hip
- C50 Breast
- C56 Ovary
- C570 Fallopian tube
- C62 Testis
- C630 Epididymis
- C64 Kidney
- C65 Renal pelvis
- C66 Ureter
- C69 Eye
- C74 Suprarenal gland

Laterality is usually 1 for the topography C342, except for rare cases with situs inversus.

- Consistency between topography/ morphology

The topography / morphology combinations include those morphologies **commonly** identified in specific primary topography (**allowed topography** codes) as well as the ones occurring only rarely or never in some specific primary topographies (**not allowed topography** codes). **Table 8** reports allowed/ not allowed combinations.

Table 8. Morphology codes and allowed/refused topography codes.

Morphology code	Allowed topography codes	Not allowed topography codes
8000-8005		C42.0, C42.1, C77 The combinations of these topographies with morphologies 8000-8005 should be reviewed and changed. If the primary site cannot be identified, topography should be C809.
8010-8589		C38, C40-C42, C47, C48.0, C49, C70-C72, C77 These combinations should be reviewed and changed. If the primary site cannot be identified, topography should be C809.
8015	C53 Any other topographies should be reviewed and changed.	
8077	C00-C15, C21, C30-C32, C44, C51-C53, C60	
8080	C60	
8081	C00, C30.0, C44, C51, C60, C63.2, C69.0, C69.1	
8082	C00-C14, C16, C30-C34, C44, C53, C65-C68, C80	
8090-8095, 8097, 8100-8103, 8110	C30.0, C44, C51, C60, C63.2 These morphology codes in lip (skin) the topography should be coded as C44.0, in breast (skin) or anus (skin) the topography should be coded as C44.5. Topographies C80 and C76 with these topographies should be reviewed and consider to code them as C44.9	
8098	C53 The combination of the morphology 8098 with another topography such as C44 should be reviewed and changed.	
8120, 8122, 8130, 8131	C56, C65-C68, C80 The combination of these morphologies with other topographies such as C64 or C61 should be reviewed and changed topography or morphology codes.	
8121	C30.0, C31, C65-C68	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
8124	C212	
8142	C16	
8144	C15-C26, C30, C31, C52, C53, C56, C67, C80	
8145	C15-C20, C25, C34, C61, C80	
8147	C00-C14, C30-C32, C50, C61 If the topography is C44 morphology should be reviewed and a possible code could be 8090.	
8148	C15-C25, C61 If the topography is C53 morphology should be reviewed and a possible code could be 8077.	
8150-8152,8154,8155	C25	
8153	C16, C17.0, C25, C80	
8156	C17.0, C25, C80	
8160,8161	C22.1, C23.9, C24.0 Other topographies such as C25 should be reviewed and changed.	
8162	C240	
8163	C22-C25	
8170-8175	C22.0	
8180	C22.1, C22.0	
8201	C15-C26, C34, C50, C54, C61, C80	
8210	C15-C26, C54	
8211	C15-C26, C34, C50, C53, C54, C56, C61, C64, C80	
8213	C18	
8214	C16	
8215	C21.1	
8220,8221	C18-C20, C26	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
8243	C18, C56, C80	
8247	C30.0, C44, C51, C60, C63.2, C80	
8250-8254	C34, C50, C61	
8256,8257	C34, C80	
8261,8262	C15-C26, C52-C57	
8263	C15-C26, C34, C52-C57, C64	
8265	C18-C20, C26	
8270-8273,8280,8281, 8300	C64, C751	
8290	C07, C08, C64, C73, C74.0, C75.1, C80	
8311,8312,8316-8320	C56, C64	
8313,8444	C56	
8314,8315	C50	
8322	C75.0	
8330-8332,8335-8337, 8339-8350	C73	
8370	C74.0	
8380-8383	C48.1, C48.2, C52-C57, C80	
8384	C53	
8390,8400,8402-8410, 8413	C30.0, C44, C51, C60, C63.2	
8401	C30.0, C44, C50, C51, C60, C63.2	
8420	C44.2	
8440	C07, C08, C18, C25, C48.1, C48.2, C50, C54, C56, C57, C80	
8441,8460	C48.1, C48.2, C53, C54, C56, C57, C80	
8442, 8450,8451,8461- 8463,8471-8474	C48.1, C48.2, C54, C56, C57	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
8452,8453	C24, C25, C56	
8470	C18.1, C25, C56, C57, C80	
8500	C07, C08, C23 -C25, C50, C61, C80	
8501-8509,8512-8514, 8519-8524,8530,8540, 8541,8543	C50	
8510	C16, C18, C50, C80 The combination topography C73 and morphology 8510 should be reviewed and changed (morphology 8345)	
8525	C00.3-C00.5, C01-C08, C30.0, C31	
8542	C30.0, C44, C51, C60, C63.2	
8550,8551	C00.3-C00.5, C01-C08, C16, C18-C20, C25, C30-C34, C50, C61, C80	
8580-8586	C37	
8588,8589	C73	
8590-8650	C56, C62	
8670	C56	
8690,8691	C755	
8692	C75.4	
8700	C74.1	
8710,8711,8714		C42.0, C42.1, C77 If the primary site cannot be identified, topography should be C809.
8720		C38, C40-C42, C47-C49, C77 If the primary site cannot be identified, topography should be C809.
8721-8723,8730	C21, C30.0, C44, C51, C60, C63.2, C69, C80	
8728	C70	
8740,8761	C44	
8741,8743,8745	C30.0, C44, C51, C60, C63.2, C69.0	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
8742	C44, C51, C60, C63.2	
8744	C44.6, C44.7, C44.9	
8746	C00-C06, C09-C11, C15, C20, C21, C30, C31, C68.0 The combination topography C44 and morphology 8746 should be reviewed and changed.	
8770-8772	C30.0, C44, C51, C60, C63.2, C69, C80	
8773,8774	C69	
8780	C44	
8800-8811,8814-8831, 8840-8921,8963,8990, 8991,9040-9043,9120- 9150,9170,9540,9550, 9561,9580,9581		C42.0, C42.1, C77 If the primary site cannot be identified, topography should be C809.
8812	C40, C41	
8832,8833	C44, C51, C60, C63.2	
8930,8931	C48.1, C48.2, C52-C57	
8933,8934	C52-C57	
8936	C15-C20, C25, C26, C48.1, C48.2, C80	
8940	C00.3-C00.5, C04-C08, C30.0, C44 If the topography is C62 morphology should be reviewed and a possible code could be 9085.	
8941	C00.3-C00.5, C04-C08, C30.0	
8950,8951	C48.1, C48.2, C52-C57, C80	
8959,8960,8964	C64	
8970	C22.0	
8971	C25	
8972,8973	C34	
8983	C50	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
9000	C56	
9013-9015	C48.1, C48.2, C56-C57, C80	
9020	C50	
9044	C49, C80	
9045	C30.0, C31, C80	
9050-9053	C38.0, C38.4, C48.1, C48.2, C63.7, C80	
9060	C38.1-C38.3, C48.0, C56, C71, C75.1, C75.3 If the topography is C62 morphology should be reviewed and a possible code could be 9064.	
9061-9063	C38.1-C38.3, C48.0, C62	
9064, 9065	C38.1-C38.3, C48.0, C49.5, C56, C62, C71, C75.1, C75.3, C80	
9070-9073, 9080-9086, 9101, 9102	C38.1-C38.3, C48.0, C49.5, C52-C57, C62, C71, C72, C75.1, C75.3, C80	
9090, 9091	C56	
9100	C38.1-C38.3, C48.0, C56-C58, C62, C80	
9104, 9105	C58	
9124	C22.0	
9161	C71-C72	
9180	C40, C41, C48.0, C49, C50, C80	
9181-9187, 9250	C40, C41	
9192-9195, 9221	C40, C41	
9220, 9230, 9231, 9240-9243	C30.0, C31, C32.3, C33, C40, C41, C48.0, C49, C80	
9251, 9252	C49	
9260, 9364		C70-C72, C42, C77
9261	C40.0, C40.2, C41.9	
9270-9342	C03, C31.0, C41.0, C41.1, C41.9	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
9350	C75.1, C75.2	
9351,9352	C75.2	
9360-9362	C75.3	
9370-9372	C11, C41, C49	
9380-9385,9391-9393,9396, 9400-9431,9440-9460,9478	C71, C72, C75.1, C75.3	
9390	C71.5, C71.9	
9394	C72	
9395	C75.3	
9432	C75.1	
9470-9472,9474-9477,9480, 9493	C71.6, C71.9	
9490,9500,9503	C38.1-C38.3, C47, C48.0, C71-C72, C74.1, C75.5, C80	
9492,9505-9509	C71, C72, C75.3	
9501,9502	C69.4, C71	
9510-9513	C69.2	
9521-9523	C30.0, C31, C72.2	
9530-9539	C70	
9560	C38, C47, C48.0, C71-C72, C80	
9582	C75.1	
9590-9596,9670-9675,9680- 9688,9690-9699,9702,9705, 9714,9715,9724,9728,9729, 9735,9737,9738,9750-9760, 9762		C42.0, C80
9597,9700,9709,9718,9725, 9726	C30.0, C44, C51, C60, C63.2 If the primary topography is not available, it should be coded as C44.9.	
9650-9667	C02.4, C09-C11, C14, C22.0, C42.1, C42.2, C77	
9678	C38.0, C38.4, C48.1, C48.2	

Table 8. *Continued*

Morphology code	Allowed topography codes	Not allowed topography codes
9679	C37.9, C38.1, C38.3, C77.1	
9689	C42.2	
9701	C42.1, C44, C77	
9708	C44, C49	
9712	C49	
9716	C22.0, C42	
9717	C16-C20, C26.0	
9719	C01-C06, C09-C14, C30-C32, C44, C69.6, C77	
9727 (BPDCN) ¹	C42.1, C44	
9731	C40, C41	
9732,9733,9742,9800-9826,9831-9920,9931-9968,9975-9989,9991,9992,9993	C42.1	
9734		C40, C41, C42.0, C42.1, C80
9741	C22.0, C42, C44, C77	
9761	C42.0	
9764	C17	
9827	C42.1, C77	
9930		C42.0, C42.1, C80

⁽¹⁾ In ICD-O-3, 9727 was used for precursor cell lymphoblastic lymphoma, NOS; in the 2011 updates to ICD-O-3, 9727 is used for blastic plasmacytoid dendritic cell neoplasm (BPDCN). The topography codes allowed refer to BPDCN only.

- Consistency between morphology/ behaviour

Although according to the Rule F of the ICD-O-3 it is exceptionally possible to have morphology and behaviour combination not listed in the ICD-O-3, it is recommended to review all records with morphology and behaviour combination not included in any version of the ICD-O-3. Nevertheless, some of these combinations are not rare among the European CRs.

Therefore, **Table 9** reports the accepted morphology and behaviour codes that are not included in the ICD-O-3.

Table 9. Accepted morphology and behaviour codes that are not included in the ICD-O-3.

8000/2	8011/2	8051/2	8053/2	8053/3	8071/2	8072/2	8075/2
8078/2	8083/2	8084/2	8100/3	8103/3	8121/2	8123/2	8124/2
8131/2	8143/2	8144/2	8160/2	8211/2	8213/2	8220/2	8221/2
8248/3	8250/2	8251/2	8252/2	8253/2	8255/2	8260/2	8262/2
8271/3	8310/2	8380/2	8382/2	8384/2	8400/2	8401/2	8402/2
8403/2	8409/2	8410/2	8440/1	8441/2	8443/3	8444/3	8480/2
8481/2	8482/2	8490/2	8502/2	8507/3	8508/2	8510/2	8540/2
8542/2	8543/2	8550/2	8560/2	8570/2	8573/2	8590/3	8721/2
8722/2	8723/2	8740/2	8743/2	8744/2	8745/2	8746/2	8770/2
8771/2	8772/2	8825/3	8832/1	8940/2	8941/2	8983/3	9013/3
9061/2	9084/2						

3.2.4 Consistency between follow-up variables, basis of diagnosis and stage

Follow-up time and extent of disease are two important components to evaluate and interpret cancer survival.

- Consistency between vital status, incidental finding of cancer at autopsy (autopsy), basis of diagnosis, duration of survival (survival) and stage

In addition to the checks between date of the last known vital status and date of incidence/date of birth described in section 3.1, **Table 10**, **Table 11**, **Table 12** include several edits related to the combination of the following variables: vital status, autopsy, basis of diagnosis and survival.

Table 10. Consistency between vital status, autopsy and basis of diagnosis.

Vital status = 1 (alive)	Autopsy (incidental finding of cancer at autopsy) should be ≠ 1 (incidentally diagnosed at autopsy)
	Basis of diagnosis ≠ 0 (DCO-Death Certificate Only)

Table 11. Consistency between basis of diagnosis, vital status, survival, dates of incidence/last known vital status and stage.

Basis of diagnosis = 0 (DCO)	Vital status = 2 (dead)
	Survival (in days) = 0
	Date of incidence = Date of the last known vital status
	Stage = 9 or blank

Table 12. Consistency between autopsy, vital status, survival and dates of incidence/last known vital status.

Autopsy = 1 (yes)	Vital status = 2 (dead)
	Survival (in days) = 0
	Date of incidence = Date of the last known vital status

3.2.5 Consistency between stage/ treatment variables and other tumour variables

The stage at diagnosis is particularly useful information for the interpretation of international survival comparisons, for the evaluation of screening programs, patient care and clinical and epidemiological research purposes.

CRs have been using TNM system for staging solid tumours and lymphomas (13, 22-25). In addition, some CRs are collecting and coding childhood cancer stage according to the Toronto guidelines (26, 27).

Table 13 contains the cancer entities and staging systems other than TNM classification used by the European CRs for coding the extent of disease for specific cancer entities.

Table 13. Staging systems other than TNM classification by cancer entities.

Staging System	Cancer entities
Ann Arbor	Lymphomas (Hodgkin Lymphoma and Non-Hodgkin lymphoma)
Lugano	Lymphomas (Hodgkin Lymphoma and Non-Hodgkin lymphoma)
Dukes'(*)	Colorectal tumours
FIGO	vulva, vagina, cervix uteri, corpus uteri, ovary and primary peritoneal carcinoma, fallopian tube, and gestational trophoblastic tumours

(*) Obsolete classification, mentioned because of historical series"

- Other additional checks related to stage and treatment variables

Behaviour and TNM/stage at diagnosis

- If behaviour >2 then pT≠pTis.
If behaviour is higher than 2 then pT category should not be coded as in situ tumour (pTis)
- If behaviour=2 then Stage = 0.
If behaviour is 2 (in situ tumour), stage should be coded as 0.

TNM/stage at diagnosis and BoD

- If pT ≠ TX and pT ≠ 9 and pT ≠ blank then BoD = 7.
If pT category has a value different than missing and unknown, the base of diagnosis should be histology and coded as 7.
- If pN ≠ NX and pN ≠ 9 and pN ≠ blank then BoD = 7.
If pN category has a value different from missing and unknown, the base of diagnosis should be coded as 7 (histology).
- If pM = 1 then BoD = 7.
cT ≠Tis and pT ≠Tis.
If pM category has the value 1 (tumour with metastasis at diagnosis) the base of diagnosis should be coded as 7 (histology). In addition the cT and pT categories cannot be coded as Tis (in situ tumour)

Treatment variables, BoD and TNM stage

- If surgery ≠ 0 or surgery ≠ 9 surgery ≠ blank then BoD = 7.
If surgery variable has a value different from zero, missing or unknown, the base of diagnosis should be coded as 7 (histology).
- If surgery = 0 then pT = 9 or pT = blank.
If surgery variable was coded as 0 (not surgery) the pT category should be coded as missing value. pT can be coded only when using the piece of the surgery.

4 Quality checklist for Multiple Primary Malignant Tumours

The Multiple Primary Malignant Tumours (MPMTs) quality checklist for **computing incidence** was developed by the JRC according to the current International Rules for Multiple Primary Cancers published in 2004(16).

The steps for checking solid MPMTs are the following:

Step 1. The two topographies are compared according to the current International Rules for Multiple Primary Cancers published in 2004.

In addition to the groups of topography codes considered as a single site in table 1 of the 2004 international rules, **for checking** other groups are considered as a single topography (see **Table 14**).

C80 (unknown primary site) and C768 (overlapping lesion of ill-defined sites) are considered as a single site with any topography.

Table 14. Groups of topography codes considered as a single site for solid tumours.

Topography code	Definition
C00 C03 C04 C05 C06 C76.0	Lip Gum Floor of mouth Palate Other and unspecified parts of mouth Head, face or neck, NOS
C01 C02 C76.0	Base of tongue Other and unspecified parts of tongue Head, face or neck, NOS
C07 C76.0	Parotid gland Head, face or neck, NOS
C08 C76.0	Other and unspecified major salivary glands Head, face or neck, NOS
C09 C10 C12 C13 C14 C76.0	Tonsil Oropharynx Pyrimiform sinus Hypopharynx Other and ill-defined sites in lip, oral cavity and pharynx Head, face or neck, NOS
C11 C76.0	Nasopharynx Head, face or neck, NOS
C15 C26.8 C26.9 C76.1	Oesophagus Overlapping lesion of digestive system Gastrointestinal tract, NOS Thorax, NOS
C16 C26.8 C26.9 C76.2	Stomach Overlapping lesion of digestive system Gastrointestinal tract, NOS Abdomen, NOS
C17 C26 C76.2	Small intestine Other and ill-defined digestive organs Abdomen, NOS

Table 14. *Continued*

Topography code	Definition
C18 C26 C76.2	Colon Other and ill-defined digestive organs Abdomen, NOS
C19 C20 C26 C76.2	Rectosigmoid junction Rectum Other and ill-defined digestive organs Abdomen, NOS
C21 C26 C76	Anus and anal canal Other and ill-defined digestive organs Other and ill-defined sites
C22 C26.8 C76.2	Liver and intrahepatic bile ducts Overlapping lesion of digestive system Abdomen, NOS
C23 C24 C268 C26.9 C76.2	Gallbladder Other and unspecified parts of biliary tract Overlapping lesion of digestive system Gastrointestinal tract, NOS Abdomen, NOS
C25 C26.8 C76.2	Pancreas Overlapping lesion of digestive system Abdomen, NOS
C30 C39 C76.0	Nasal cavity and middle ear Other and ill-defined sites within respiratory system and intrathoracic organs Head, face or neck, NOS
C31 C39 C76.0	Accessory sinuses Other and ill-defined sites within respiratory system and intrathoracic organs Head, face or neck, NOS
C32 C39 C76.0	Larynx Other and ill-defined sites within respiratory system and intrathoracic organs Head, face or neck, NOS
C33 C34 C39 C76.0 C76.1	Trachea Bronchus and lung Other and ill-defined sites within respiratory system and intrathoracic organs Head, face or neck, NOS Thorax, NOS
C37 C76.1	Thymus Thorax, NOS
C38 C39.8 C76.1	Heart, mediastinum, and pleura Overlapping lesion of respiratory system and intrathoracic organs Thorax, NOS
C39 C76.0 C76.1	Other and ill-defined sites within respiratory system and intrathoracic organs Head, face or neck, NOS Thorax, NOS
C40 C41 C76	Bones, joints and articular cartilage of limbs Bones, joints and articular cartilage of other and unspecified sites Other and ill-defined sites

Table 14. *Continued*

Topography code	Definition
C44	Skin
C76	Other and ill-defined sites
C47	Peripheral nerves and autonomic nervous system
C76	Other and ill-defined sites
C48	Retroperitoneum and peritoneum
C76	Other and ill-defined sites
C49	Connective, subcutaneous and other soft tissues
C76	Other and ill-defined sites
C50	Breast
C76.1	Thorax, NOS
C51	Vulva
C57.8	Overlapping lesion of female genital organs
C57.9	Female genital tract, NOS
C76.3	Pelvis, NOS
C52	Vagina
C57.8	Overlapping lesion of female genital organs
C57.9	Female genital tract, NOS
C76.3	Pelvis, NOS
C53	Cervix uteri
C55	Uterus, NOS
C57.8	Overlapping lesion of female genital organs
C57.9	Female genital tract, NOS
C76.3	Pelvis, NOS
C54	Corpus uteri
C55	Uterus, NOS
C57.8	Overlapping lesion of female genital organs
C57.9	Female genital tract, NOS
C76.3	Pelvis, NOS
C56	Ovary
C57.8	Overlapping lesion of female genital organs
C57.9	Female genital tract, NOS
C76.3	Pelvis, NOS
C57	Other and unspecified female genital organs
C76.3	Pelvis, NOS
C58	Placenta
C76.3	Pelvis, NOS
C60	Penis
C63.8	Overlapping lesion of male genital organs
C63.9	Male genital organs, NOS
C76.3	Pelvis, NOS
C61	Prostate gland
C63.8	Overlapping lesion of male genital organs
C63.9	Male genital organs, NOS
C76.3	Pelvis, NOS

Table 14. Continued

Topography code	Definition
C62 C63.8 C63.9 C76.3	Testis Overlapping lesion of male genital organs Male genital organs, NOS Pelvis, NOS
C63 C76.3	Other and unspecified male genital organs Pelvis, NOS
C64 C68.8 C68.9 C76	Kidney Overlapping lesion of urinary organs Urinary system, NOS Other and ill-defined sites
C65 C66 C67 C68 C76	Renal pelvis Ureter Bladder Other and unspecified urinary organs Other and ill-defined sites
C69 C76.0	Eye and adnexa Head, face or neck, NOS
C70 C76.0	Meninges Head, face or neck, NOS
C71 C76.0	Brain Head, face or neck, NOS
C72 C76.0	Spinal cord, cranial nerves, and other parts of central nervous system Head, face or neck, NOS
C73 C76.0	Thyroid Head, face or neck, NOS
C74 C76	Adrenal gland Other and ill-defined sites
C75 C76	Other endocrine glands and related structures Other and ill-defined sites

Note: topography codes C80 and C768 are considered as a single site in combination with any other topography.

- a) If the two topographies are in the same group, the two morphologies should be compared (**step 2**).
- b) If the two topographies are in different groups, each tumour should be considered as primary tumour.

Step 2. The two morphologies should be compared according to the “*groups of malignant neoplasms considered to be histologically ‘different’ for the purpose of defining multiple tumours, ICD-O-3.2*” prepared by the International Agency for Research on Cancer (IARC) and the International Association of Cancer Registries (IACR) (14).

Some unspecified morphologies were included **for checking** in the groups defined by the IACR/IACR (**Table 15**). Morphology codes 8000-8005 (Unspecified types of cancer) are considered as a single group in combination with any other morphology.

Note: For haematological malignancies, Kaposi sarcoma and mesothelioma only morphologies are compared

Table 15. Groups of morphology codes considered as a single entity.

Morphology code	Definition
8051-8086, 8120-8131 8010-8015, 8020-8022, 8050 8000-8005	Squamous and transitional cell carcinoma Unspecified carcinomas (NOS) Unspecified types of cancer
8090-8110 8010-8015, 8020-8022, 8050 8000-8005	Basal cell carcinomas Unspecified carcinomas (NOS) Unspecified types of cancer
8140-8149, 8160-8163, 8190-8221, 8250-8552, 8570-8576, 8940-8941, 9110 8010-8015, 8020-8022, 8050 8000-8005	Adenocarcinomas Unspecified carcinomas (NOS) Unspecified types of cancer
8023, 8030-8046, 8150-8158, 8170-8180, 8230-8249, 8560-8562, 8580-8589 8010-8015, 8020-8022, 8050 8000-8005	Other specific carcinomas Unspecified carcinomas (NOS) Unspecified types of cancer
8680-8714, 8800-8921, 8930-8936, 8990-8992, 9040-9045, 9120-9125, 9130-9138, 9141-9252, 9370-9373, 9540-9582 8000-8005	Sarcomas and soft tissue tumours Unspecified types of cancer
9050-9055 8000-8005	Mesothelioma Unspecified types of cancer
9840, 9860-9931, 9945-9946, 9950, 9960-9964, 9966, 9975, 9980-9989, 9991-9993 9590-9591, 9596, 9727, 9760, 9800-9801, 9805-9809, 9820, 9832, 9835, 9965, 9967-9968, 9970-9971 8000-8005	Myeloid Unspecified types of haematopoietic and lymphoid tissues Unspecified types of cancer
9597, 9670-9699, 9712, 9728, 9731-9738, 9761-9767, 9769, 9811-9819, 9823, 9826, 9833, 9836, 9940 9590-9591, 9596, 9727, 9760, 9800-9801, 9805-9809, 9820, 9832, 9835, 9965, 9967-9968, 9970-9971 8000-8005	B-cell neoplasms Unspecified types of haematopoietic and lymphoid tissues Unspecified types of cancer
9700-9709, 9714-9719, 9724-9726, 9729, 9768, 9827, 9831, 9834, 9837, 9948 9590-9591, 9596, 9727, 9760, 9800-9801, 9805-9809, 9820, 9832, 9835, 9965, 9967-9968, 9970-9971 8000-8005	T-cell and NK-cell neoplasms Unspecified types of haematopoietic and lymphoid tissues Unspecified types of cancer

Table 15. *Continued*

Morphology code	Definition
9650-9667 9590-9591, 9596, 9727, 9760, 9800-9801, 9805-9809, 9820, 9832, 9835, 9965, 9967- 9968, 9970- 9971 8000-8005	Hodgkin lymphoma Unspecified types of haematopoietic and lymphoid tissues Unspecified types of cancer
9740-9742 9590-9591, 9596, 9727, 9760, 9800-9801, 9805-9809, 9820, 9832, 9835, 9965, 9967- 9968, 9970- 9971 8000-8005	Mast-cell tumours Unspecified types of haematopoietic and lymphoid tissues Unspecified types of cancer
9749, 9750-9759 9590-9591, 9596, 9727, 9760, 9800-9801, 9805-9809, 9820, 9832, 9835, 9965, 9967- 9968, 9970- 9971 8000-8005	Histiocytes and Accessory Lymphoid cells Unspecified types of haematopoietic and lymphoid tissues Unspecified types of cancer
9140 8000-8005	Kaposi sarcoma Unspecified types of cancer
8590-8671, 8720-8790, 8950-8983, 9000-9030, 9060-9105, 9260-9365, 9380-9539 8000-8005	Other specified types of cancer Unspecified types of cancer

The 2004 International Rules for Multiple Primary Cancer also includes some **recommendations for recording tumours** related to: 1) tumours of different laterality with the same morphology diagnosed in paired organs; 2) cancers which occur in any 4th character subcategory of colon (C18) and skin(C44) (16).

In addition to the recommendations for recording tumours described in the 2004 International rules for Multiple Primary Cancer, the **ENCR recommendation** for **recording** tumours is to register separately tumours in the same patient when the 3 digits of ICD-O-3 topography are different even if they have the same morphology.

An exception to the mentioned recommendation is where one tumour has a non-specific topography which covers a range of sites (e.g. C26, C80) and the other has a topography within this range of sites; these should be considered to be in the same organ.

This approach is giving more flexibility to the data use by clinicians, epidemiologist, policymakers and researchers.

Following this recommendation, for example, a renal pelvis tumours (C65) with 8120 morphology code diagnosed in a patient with bladder tumour (C67) with 8130 morphology code, both tumours should be registered, even if morphologies are in the same group. Nevertheless, a bladder tumour (C67) in the a patient with urinary system NOS (C68.9) or unknown primary site (C80.9), only bladder tumour should be registered if the morphologies are included in the same group according to the **Table 15**.

5 Conclusions

The JRC Technical report “A common data quality check procedure for European cancer registries” is the result of a collaboration between the JRC and ENCR to improve the data quality and harmonization among the European population-based CRs enabling accurate comparisons of European cancer information data.

The report focuses on the internal consistency of cancer registry data validation. It was prepared taking into account the current European and International standards and classifications, as well as the lessons learned from the European CRs that submitted data in the 2015 ENCR-JRC data call.

It is the framework for updating the Quality Check Software developed by the JRC and for validating the CR data contributing to the European Cancer Information System (ECIS).

References

1. Parkin DM. The evolution of the population-based cancer registry. *Nat Rev Cancer*. 2006; 6: 603-12.
2. Parkin DM. The role of cancer registries in cancer control. *Int J Clin Oncol*. 2008; 13: 102-111.
3. Siesling S, Louwman WJ, Kwast A, et al. Uses of cancer registries for public health and clinical research in Europe: Results of the European Network of Cancer Registries survey among 161 population-based cancer registries during 2010-2012. *Eur J Cancer*. 2015; 51: 1039-49.
4. Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. *Eur J Cancer* 2009; 45: 747-55.
5. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: Principles and methods Part II. Completeness. *Eur J Cancer* 2009; 45: 756-64.
6. Ferlay J, Burkhard C, Whelan S, Parkin, DM. Check and conversions programs for cancer registries: IARC/IACR tools for cancer registries. International Association for Research on Cancer; Lyon: 2005.
7. EUROCARE. Checking procedures of the EUROCARE-4 Data Base. Available at <http://www.eurocare.it/Eurocare4DataChecking/tabid/81/Default.aspx>.
8. De Angelis R, Francisci S, Baili P et al. The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. *Eur J Cancer*, 2009, 45: 909-930.
9. Allemani C, Weir HK, Carreira H et al. and the CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*, 2015, 385 (9972): 977-1010.
10. Martos C, Crocetti E, Visser O, Rous B and the Data Quality Check Working Group. A proposal on cancer data quality checks: one common procedure for European cancer registries. EUR 27008. Luxembourg (Luxembourg): Publications Office of the European Union; 2014. JRC93456
11. Martos C, Crocetti E, Visser O, Rous B, Giusti F and the Data Quality Check Working Group. A proposal on cancer data quality checks: one common procedure for European cancer registries –version 1.1, EUR 29089 EN. Publications Office of the European Union, Luxembourg, 2018. JRC105078.
12. International Agency for Research on Cancer. ICD-O-Third Edition, Second Revision Morphology. Available at http://www.iacr.com.fr/images/Newsflash/ICD-O-3.2_final_update09102020.xls.
13. Brierley JD, Gospodarowicz MK, Wittekind Ch, eds. TNM Classification of Malignant Tumors. 8th ed., Wiley-Blackwell, Oxford, 2017.
14. International Association of Cancer Registries/International Agency for Research on Cancer. Groups of malignant neoplasms considered to be histologically 'different' for the purpose of defining multiple tumours. Available at http://www.iacr.com.fr/images/Newsflash/ICD-O-3.2Changes_update09102020.xls
15. Call for Data Protocol for European Population-Based Cancer Registries. Available at https://www.enrcr.eu/sites/default/files/inline-files/ECIS%20call%20for%20data%20protocol_20220317_0.pdf.
16. IACR/IARC/ENCR. International Rules for Multiple Primary Cancers. IARC, Lyon, 2004. Available at https://www.enrcr.eu/sites/default/files/pdf/MPrules_july2004.pdf.
17. EUROSTAT. European Commission. Nomenclature of territorial units for statistics. Available at <https://ec.europa.eu/eurostat/web/nuts/background>.
18. ENCR Recommendations. Coding Incidence Data, 2022. Available at https://www.enrcr.eu/sites/default/files/Recommendations/ENCR%20Recommendation%20DOI_Mar2022_0.pdf

19. ENCR Recommendations for coding Basis if diagnosis, 1999. Available at https://encr.eu/sites/default/files/Recommendations/ENCR%20Recommendation%20BoD_Oct2022_EN_241022.pdf
20. Fritz A, Percy C, Jack A, Shanmugarathan K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology, Third Edition, First Revision (ICD-O-3.1). World Health Organization, 2013.
21. ENCR recommendations 2022. Recording and Reporting of Urothelial Tumours of the Urinary Tract. Available at https://www.encr.eu/sites/default/files/Recommendations/ENCR%20Recommendation_UT_Jun2022_EN.pdf.
22. Hermanek P, Sobin LH, eds. TNM classification of malignant tumours. 4th Ed, Springer-Verlag, Berlin 1987 [revised 1992]
23. Sobin LH, Wittekind Ch, eds. TNM classification of malignant tumours. 5th Ed., John Wiley & Sons, New York, 1997
24. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours. 6th ed., John Wiley & Sons, Hoboken, New Jersey, 2002.
25. Sobin LH, Gospodarowicz MK, Wittekind Ch, eds. TNM Classification of Malignant Tumors. 7th ed, Wiley-Blackwell, Oxford, 2009.
26. Aitken JF, Youlden DR, Moore AS, Baade PD, Ward LJ, Thursfield VJ, Valery PC, Green AC, Gupta S, Frazier AL. Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2017
27. Aitken JF, Youlden D, O'Neill L, Gupta S, Frazier AL, eds. Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines – Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021. Available at <https://cancerqld.blob.core.windows.net/content/docs/childhood-cancer-staging-for-population-registries.pdf>.
28. User's Guide to ESSENTIAL TNM (E TNM). Version 3 _8 Cancer Sites (April 2022). Available at https://www.uicc.org/sites/default/files/atoms/files/Essential%20TNM%20Users%20Guide_Version%203_8%20sites%201%20Apr%202022_ENG.pdf.
29. Anatomical Therapeutic Chemical (ATC) classification system. WHO Collaborating Centre for Drug Statistics. Available at http://www.whoccno/atc_ddd_index/.

List of abbreviations and definitions

ENCR	European Network of Cancer Registries
IACR	International Association of Cancer Registries
IARC	International Agency for Research on Cancer
CRs	Cancer registries
MPMT	Multiple Primary Malignant Tumours

List of figures

Figure 1. Range of values for the variable 'day' according to variables 'month 'and 'year'12

List of tables

Table 1. Variable description, missing/unknown and allowed values.....	5
Table 2. Unlikely and rare combinations of age and tumour type.....	14
Table 3. Invalid sex and topography combinations.....	16
Table 4. Valid combinations for basis of diagnosis, morphology and behaviour by topography.....	17
Table 5. Valid morphology and grade combinations for urothelial tumours and ductal carcinoma in situ of breast with behaviour less than 3.....	20
Table 6. Valid morphology and grade combinations for haematological malignancies.....	20
Table 7. Morphology code and description, and correct associated grade for ICD-O-3 terms with implied statement of grade.....	21
Table 8. Morphology codes and allowed/refused topography codes.....	23
Table 9. Accepted morphology and behaviour codes that are not included in the ICD-O-3.....	31
Table 10. Consistency between vital status, autopsy and basis of diagnosis.....	31
Table 11. Consistency between basis of diagnosis, vital status, survival, dates of incidence/last known vital status and stage.....	32
Table 12. Consistency between autopsy, vital status, survival and dates of incidence/last known vital status.....	32
Table 13. Staging systems other than TNM classification by cancer entities.....	32
Table 14. Groups of topography codes considered as a single site for solid tumours.....	34
Table 15. Groups of morphology codes considered as a single entity.....	38

GETTING IN TOUCH WITH THE EU

In person

All over the European Union there are hundreds of Europe Direct centres. You can find the address of the centre nearest you online (european-union.europa.eu/contact-eu/meet-us_en).

On the phone or in writing

Europe Direct is a service that answers your questions about the European Union. You can contact this service:

- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls),
- at the following standard number: +32 22999696,
- via the following form: european-union.europa.eu/contact-eu/write-us_en.

FINDING INFORMATION ABOUT THE EU

Online

Information about the European Union in all the official languages of the EU is available on the Europa website (european-union.europa.eu).

EU publications

You can view or order EU publications at op.europa.eu/en/publications. Multiple copies of free publications can be obtained by contacting Europe Direct or your local documentation centre (european-union.europa.eu/contact-eu/meet-us_en).

EU law and related documents

For access to legal information from the EU, including all EU law since 1951 in all the official language versions, go to EUR-Lex (eur-lex.europa.eu).

Open data from the EU

The portal data.europa.eu provides access to open datasets from the EU institutions, bodies and agencies. These can be downloaded and reused for free, for both commercial and non-commercial purposes. The portal also provides access to a wealth of datasets from European countries.

The European Commission's science and knowledge service

Joint Research Centre

JRC Mission

As the science and knowledge service of the European Commission, the Joint Research Centre's mission is to support EU policies with independent evidence throughout the whole policy cycle.



EU Science Hub
joint-research-centre.ec.europa.eu

 @EU_ScienceHub

 EU Science Hub - Joint Research Centre

 EU Science, Research and Innovation

 EU Science Hub

 EU Science